UC Berkeley-linked cell biology technology developer Berkeley Lights floated in a $178m offering and its shares almost tripled in price on their first day of trading.

The Nikon and Varian-backed cell biology technology developer floated in a $178m offering and its shares almost tripled in price on their first day of trading.

The Roche and GSK-backed autoimmune disease drug developer has gone public in an upsized initial public offering after at least $138m in earlier funding.

The oncology therapy developer has gone public in an upsized offering that provided an exit to Third Rock Ventures.

The EV battery producer has gone public in China, weeks after raising $193m in a round featuring strategic partner Daimler.

The oncology therapy developer has gone public in an upsized offering that provided exits for SoftBank Vision Fund and Alphabet's GV unit.

UPMC's patient telemedicine service Curavi Health has completed a merger that enables its founding institution to retain an equity stake.

The ophthalmologic drug developer has gone public three years after being founded by WuXi AppTec-backed 6 Dimensions Capital.

University of Toronto and McMaster University-founded glioblastoma Car T-cell therapy developer Empirca Therapeutics has been acquired by Century Therapeutics.

The banking software provider's shares have nearly tripled following an offering in which it floated well above its range.